14
total announcements
524212.BO · 15 min delayed
Wanbury Ltd
Wanbury Ltd has announced the 38th Annual General Meeting to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM) on September 24, 2026.
Wanbury Ltd
Wanbury Ltd will hold its 38th Annual General Meeting (AGM) on September 24, 2026, and its register of members and share transfer books will be closed from September 18-24, 2026.
Wanbury Ltd
Wanbury Ltd's Annual Report 2025-26 and Notice of the 38th Annual General Meeting were submitted to BSE and NSE. The report includes financial statements, auditor's report, and a notice for the AGM on September 24, 2026.
Wanbury Ltd
Wanbury Ltd has announced its 38th Annual General Meeting to be held on September 24, 2026, through video conferencing. The meeting will consider the audited financial statements for the year ended March 31, 2026, and other business.
Wanbury Ltd
Wanbury Ltd has published a notice in newspapers regarding its 38th Annual General Meeting to be held on September 24, 2026, through video conferencing.
Wanbury Ltd
Wanbury Ltd received approval from EDQM for new product Rivaroxaban API, and also received DMF clearance for Paraxetine HCI and Metformin HCI from USFDA.
Wanbury Ltd
Wanbury Ltd announced the outcome of its Board Meeting held on August 11, 2026, where it approved the un-audited financial results for the first quarter and three months ended June 30, 2026. The company also approved the allotment of 27,530 equity shares to eligible employees under the Employee Stock Option Plan 2016, and the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director.
Wanbury Ltd
Wanbury Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 165.6 crore, a 1.5% YoY growth, and PAT at Rs. 3.2 crore, a 76.0% decline from Q1 FY26. The company has completed a refinancing of its existing debt facilities, reduced its borrowing cost, and cleared regulatory inspections at its API sites.
Wanbury Ltd
Wanbury Ltd has announced its Q1 FY2026 un-audited financial results, approved the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director, and allotted 27,530 equity shares to eligible employees under the Wanbury Limited Employee Stock Option Plan 2016.
Wanbury Ltd
Wanbury Ltd has announced its financial results for the first quarter ended 30th June, 2026. The company has approved the un-audited financial results, which will be uploaded on its website. Additionally, the board has approved the allotment of 27,530 equity shares to eligible employees who have exercised their vested options under the Wanbury Limited Employee Stock Option Plan 2016. The paid-up share capital of the company will increase from Rs. 34,93,93,000 to Rs. 34,96,69,280. The board has also approved the re-appointment of Mr. Mohan Kumar Rayana as a whole-time director for a term of five years.
Wanbury Ltd
Wanbury Ltd's Board of Directors approved un-audited financial results for Q1 FY2026, and also approved the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for 5 years. The company also allotted 27,530 equity shares to eligible employees upon exercise of vested options.
Wanbury Ltd
Wanbury Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 11/08/2026 to consider and approve the Un-audited Financial Results for the first quarter and three months ended June 30, 2026.
Wanbury Ltd
Wanbury Ltd received 'No DMF deficiency letter' from USFDA for multiple ANDAs, indicating full compliance with regulatory requirements.
Wanbury Ltd
Wanbury Ltd has completed a routine inspection by the USFDA at its facility in Tanuku, West Godavari District, Andhra Pradesh. The inspection resulted in six observations, and the company will respond to these within the stipulated time. The company does not anticipate any impact on its operations or exports to the US and other international markets.